Idioma:

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Milà-Alomà, Marta ; Ashton, Nicholas J ; Shekari, Mahnaz ; Salvadó, Gemma ; Ortiz-Romero, Paula ; Montoliu-Gaya, Laia ; Benedet, Andrea L ; Karikari, Thomas K ; Lantero-Rodriguez, Juan ; Vanmechelen, Eugeen ; Day, Theresa A ; González-Escalante, Armand ; Sánchez-Benavides, Gonzalo ; Minguillon, Carolina ; Fauria, Karine ; Molinuevo, José Luis ; Dage, Jeffrey L ; Zetterberg, Henrik ; Gispert, Juan Domingo ; Suárez-Calvet, Marc ; Blennow, Kaj

Nature medicine, 2022-09, Vol.28 (9), p.1797-1801 [Periódico revisado por pares]

New York: Nature Publishing Group

Texto completo disponível

Citações Citado por

Enviar para

Título:
Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
Autor: Milà-Alomà, Marta ; Ashton, Nicholas J ; Shekari, Mahnaz ; Salvadó, Gemma ; Ortiz-Romero, Paula ; Montoliu-Gaya, Laia ; Benedet, Andrea L ; Karikari, Thomas K ; Lantero-Rodriguez, Juan ; Vanmechelen, Eugeen ; Day, Theresa A ; González-Escalante, Armand ; Sánchez-Benavides, Gonzalo ; Minguillon, Carolina ; Fauria, Karine ; Molinuevo, José Luis ; Dage, Jeffrey L ; Zetterberg, Henrik ; Gispert, Juan Domingo ; Suárez-Calvet, Marc ; Blennow, Kaj
Assuntos: Alzheimer's disease ; Biochemistry & Molecular Biology ; Biochemistry and Molecular Biology ; Biokemi och molekylärbiologi ; biomarker ; Biomarkers ; Blood ; Brief Communication ; Cell Biology ; Clinical trials ; Glial fibrillary acidic protein ; Medicine ; Neurodegenerative diseases ; Pathology ; phosphorylated tau 181 ; Plasma ; Positron emission ; Positron emission tomography ; Research & Experimental ; Tomography ; β-Amyloid
É parte de: Nature medicine, 2022-09, Vol.28 (9), p.1797-1801
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Abstract Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer’s disease are needed to facilitate the initial screening process of participants in disease-modifying trials. Previous biofluid data suggest that phosphorylated tau231 (p-tau231) could indicate incipient Aβ pathology, but a comprehensive comparison with other putative blood biomarkers is lacking. In the ALFA+ cohort, all tested plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL and Aβ42/40) were significantly changed in preclinical Alzheimer’s disease. However, plasma p-tau231 reached abnormal levels with the lowest Aβ burden. Plasma p-tau231 and p-tau217 had the strongest association with Aβ positron emission tomography (PET) retention in early accumulating regions and associated with longitudinal increases in Aβ PET uptake in individuals without overt Aβ pathology at baseline. In summary, plasma p-tau231 and p-tau217 better capture the earliest cerebral Aβ changes, before overt Aβ plaque pathology is present, and are promising blood biomarkers to enrich a preclinical population for Alzheimer’s disease clinical trials.
Editor: New York: Nature Publishing Group
Idioma: Inglês

Links

View record from Swedish Publication Index

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

New York: Nature Publishing Group

Buscando em bases de dados remotas. Favor aguardar.